Molecular Templates, Inc. (MTEM)
NASDAQ: MTEM · IEX Real-Time Price · USD
1.650
+0.010 (0.61%)
At close: May 1, 2024, 4:00 PM
1.720
+0.070 (4.24%)
After-hours: May 1, 2024, 5:25 PM EDT
Molecular Templates Revenue
In the year 2023, Molecular Templates had annual revenue of $57.31M with 190.10% growth. Revenue in the quarter ending December 31, 2023 was $7.02M with 168.71% year-over-year growth.
Revenue (ttm)
$57.31M
Revenue Growth
+190.10%
P/S Ratio
0.15
Revenue / Employee
$924,290
Employees
62
Market Cap
8.87M USD
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 57.31M | 37.55M | 190.10% |
Dec 31, 2022 | 19.75M | -18.94M | -48.95% |
Dec 31, 2021 | 38.70M | 19.85M | 105.34% |
Dec 31, 2020 | 18.85M | -3.43M | -15.38% |
Dec 31, 2019 | 22.27M | 8.99M | 67.63% |
Dec 31, 2018 | 13.29M | 9.89M | 291.31% |
Dec 31, 2017 | 3.40M | 1.52M | 80.59% |
Dec 31, 2016 | 1.88M | -75.04M | -97.56% |
Dec 31, 2015 | 76.92M | 62.19M | 422.45% |
Dec 31, 2014 | 14.72M | 2.23M | 17.82% |
Dec 31, 2013 | 12.50M | 6.63M | 112.97% |
Dec 31, 2012 | 5.87M | 5.81M | 9,362.90% |
Dec 31, 2011 | 62.00K | - | - |
Dec 31, 2010 | 0 | - | - |
Dec 31, 2009 | 0 | - | - |
Dec 31, 2008 | 1.44M | 4.00K | 0.28% |
Dec 31, 2007 | 1.44M | -25.00K | -1.71% |
Dec 31, 2006 | 1.46M | 771.00K | 111.74% |
Dec 31, 2005 | 690.00K | - | - |
Dec 31, 2004 | 0 | - | - |
Dec 31, 2003 | 0 | - | - |
Dec 31, 2002 | 0 | - | - |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
Biofrontera | 34.07M |
TRxADE HEALTH | 8.27M |
NeuroMetrix | 5.90M |
Aeterna Zentaris | 4.50M |
Vaccinex | 570.00K |
Inhibikase Therapeutics | 260.50K |
BioRestorative Therapies | 145.80K |
MTEM News
- 22 days ago - Molecular Templates Presents Interim Data from MT-6402 Phase I Study in Patients with PD-L1+ Solid Tumors at the 2024 American Association for Cancer Research (AACR) Annual Meeting; Monotherapy Activity in Checkpoint-Experienced Head and Neck Cancer Patients Observed Through Novel Immuno-oncology Mechanism - GlobeNewsWire
- 4 weeks ago - Molecular Templates, Inc. Reports Fourth Quarter 2023 Financial Results and Business Update - GlobeNewsWire
- 4 weeks ago - Molecular Templates Announces $9.5 Million Private Placement Offering and Agreement to Amend Second Tranche of July 2023 Purchase Agreement - GlobeNewsWire
- 6 weeks ago - Top 5 Health Care Stocks Which Could Rescue Your Portfolio In March - Inspire Veterinary (NASDAQ:IVP), Fractyl Health (NASDAQ:GUTS) - Benzinga
- 2 months ago - Molecular Templates, Inc. Provides Interim Update - GlobeNewsWire
- 2 months ago - Molecular Templates to Present at Oppenheimer 34th Annual Healthcare Life Sciences Conference - GlobeNewsWire
- 6 months ago - Molecular Templates, Inc. Reports Third Quarter 2023 Financial Results and Business Update - GlobeNewsWire
- 6 months ago - Molecular Templates Announces First Patient Dosed in Phase 1 Trial Evaluating MT-8421, a Novel Engineered Toxin Body Targeting CTLA-4, in Advanced Solid Tumors - GlobeNewsWire